EFPIA - NEWSLETTER

EFPIA Newsletter 19 May 2022

International Clinical Trials Day

19 May 2022 Enhancing public health through responsible Clinical Trials Data Sharing

International Clinical Trials Day: EFPIA’s commitment to advancing data transparency in a changing world

19 May 2022 Digital Health Technologies in Drug Development

Accelerating the momentum in Europe

19 May 2022 Complex Clinical Trials – A decade of innovation in clinical research

From a Drug centric to a Patient centric approach

#WeWontRest until we beat cancer

17 May 2022 Bladder Cancer Awareness Month: an opportunity for collaborative action to address pressing...

As our understanding of predictive biomarkers grows, we have the potential to change what a cancer diagnosis means for...

18 May 2022 Bladder cancer: the Cinderella of cancers

Prioritising bladder cancer in EU health policy and research frameworks can help reduce disease burden and support progress...

16 May 2022 Revising the EU Council Recommendation on cancer screening: an opportunity to step up the fight...

We are committed to working with all stakeholders to achieve tangible progress for patients with cancer, keeping the...

Events

02 JUN 2022

mportance of Diversity & Equal Opportunities in a Healthy R&D Environment - Workforce... June 2, 14:00-15:30 CET

Workforce and Organizational Culture

Learn more →

07 JUN 2022

Future Clinical Trials conference – from tomorrow to 2030 – Why choose the Nordics?... in Helsinki or virtually

The event will take place in Team Finland House (Porkkalankatu 1, Helsinki). It is also possible to follow the event...

Learn more →

We published

Cardiovascular disease (CVD) is Europe’s number one killer, taking the lives of 5,000 Europeans every day. A new report by PwC, commissioned by the EFPIA CVD Network, set out to understand the impact of the pandemic on the 60 million CVD patients living in Europe. More than that, the report – Boosting cardiovascular health in Europe: towards more resilient and equitable healthcare – offers a series of concrete recommendations designed to better position European health systems to cope with future crises.

What we are reading

France is making innovative drugs more accessible, but it can still do better 16 May 2022 (Le Monde)

Finance, culture, talent: why Europe struggles to commercialise its biotech expertise 21 March 2022 (Financial Times)

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
Communications@efpia.eu

▶